Abstract：Objective：To evaluate the feasibility of detecting KRASand BRAF mutations in the patients with nonsmall cell lung cancer (NSCLC) by high resolution melting curve analysis (HRM). Methods：The mutations of KRAS exon 2 and BRAF exon 15 in 64 patients with NSCLC were detected by HRM analysis and direct sequencing. Results：KRAS exon 2 mutations were detectable in 9 patients (14.1%), and BRAF exon 15 mutations were detectable in 4 patients（6.25%） by both the two methods. KRAS mutations were comprised of 4 different mutant alleles. G12C showed the highest mutation rate (44.4%). The mutations type of BRAF in exon 15 were all V600E. The concordant rate between the two methods was 100%. Conclusion：Compared with direct sequencing, HRM analysis for detecting KRAS andBRAF should be an accurate, convenient, efficient and economical assay which is suitable for clinical application.